Brind.

Morgan Stanley raised price targets on Halozyme Therapeutics, noting the company may benefit from Trump-era tariffs.

3 reports, 1 independent Updated Aug 7

Gone quiet

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Morgan Stanley raised price targets on Halozyme Therapeutics, noting the company may benefit from Trump-era tariffs.

Who's involved

What this event is mainly about

Donald Trump Morgan Stanley Halozyme Therapeutics

Keep exploring

The entities involved

Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
- Trump ended the ceasefire agreement with Iran following recent attacks by Iranian forces.Mon 18:02
- The Trump administration utilized the Department of Health & Human Services for an AI tool.Mon 18:02
Morgan Stanley
U.S. investment bank
- Financial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Mon 17:33
- Goldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Mon 17:24
Halozyme Therapeutics
Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 29Insider MonkeyMorgan Stanley Raises PT on Halozyme Therapeutics (HALO) to $80 From $75 Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best high growth low PE stocks to invest in now. Morgan Stanley raised
Aug 29Insider MonkeyMorgan Stanley Raises PT on Halozyme Therapeutics (HALO), After Q2 Results Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On Augus

1 more outlet ran the same wire story

Aug 7themarketsdaily.com